Starpharma Holdings Ltd has released a press release.
AGM Chair's address and CEO's presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
In the deck
Earlier from Starpharma
- SPL7013 Nasal Spray Australia Update
- Starpharma Receives $5.5M R&D Tax Incentive Refund
- Annual Report to shareholders
- Positive final DEP irinotecan Phase 2 clinical trial results
- Starpharma Business Update
Later from Starpharma
- SPL receives positive FDA feedback on DEP SN38 for PROC
- 2025 Appendix 4E Preliminary Financial Report
- FY25 Key Financial Results and Annual Report
- $3.7M R&D Tax Incentive Received
- Starpharma Announces License Agreement with Genentech
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma